Literature DB >> 25139496

Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer.

Charushila Yuvraj Kadam1, Subodhini A Abhang2.   

Abstract

BACKGROUND: Anticancer agents used in chemotherapy for tumors induce apoptosis in malignant cells. Soluble Fas ligand, granzyme B and cytochrome c are key elements in the process of apoptosis. The objective of this preliminary study was to evaluate the changes in the serum concentrations of these parameters in breast cancer patients undergoing adjuvant chemotherapy.
MATERIALS AND METHODS: Sixty patients with histopathologically proven breast cancer were included in the present study. The blood samples were taken after surgery before chemotherapy and after 3weeks of administration of the first cycle of chemotherapy. Thirty healthy female controls were selected for comparison. Soluble FasL, granzyme B and cytochrome c were estimated from serum by ELISA.
RESULTS: Significantly increased concentrations of soluble FasL, granzyme B and cytochrome c were found in stage II and stage III of breast cancer patients after chemotherapy compared with concentrations before chemotherapy (P<0.0001). A significant positive correlation was found between soluble FasL and cytochrome c as well as between granzyme B and cytochrome c in breast cancer patients after chemotherapy.
CONCLUSION: Serum concentrations of apoptotic markers such as soluble FasL, granzyme B and cytochrome c were increased after administration of the first cycle of chemotherapeutic drugs. The measurement of these circulating apoptotic markers may help clinicians in evaluating treatment efficacy in breast cancer.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant chemotherapy; Apoptosis; Breast cancer; Cytochrome c; Fas ligand; Granzyme B

Mesh:

Substances:

Year:  2014        PMID: 25139496     DOI: 10.1016/j.cca.2014.08.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  A label-free RTP sensor based on aptamer/quantum dot nanocomposites for cytochrome c detection.

Authors:  Dongxia Li; Junping Guo; Liang Zhao; Guoxian Zhang; Guiqin Yan
Journal:  RSC Adv       Date:  2019-10-08       Impact factor: 4.036

2.  Identification of differentially expressed proteins in Ostrinia furnacalis adults after exposure to ultraviolet A.

Authors:  Changyu Zhang; Jianyu Meng
Journal:  Environ Sci Pollut Res Int       Date:  2018-06-23       Impact factor: 4.223

3.  A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?

Authors:  A Coosemans; T Baert; I Vergote
Journal:  Facts Views Vis Obgyn       Date:  2015

4.  Study of the tumor microenvironment during breast cancer progression.

Authors:  Rahil Eftekhari; Rezvan Esmaeili; Reza Mirzaei; Katayoon Bidad; Stacy de Lima; Maryam Ajami; Hedayatollah Shirzad; Jamshid Hadjati; Keivan Majidzadeh-A
Journal:  Cancer Cell Int       Date:  2017-12-22       Impact factor: 5.722

5.  Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer.

Authors:  Yulong Bao; Li Wang; Lin Shi; Fen Yun; Xia Liu; Yongxia Chen; Chen Chen; Yanni Ren; Yongfeng Jia
Journal:  Cell Mol Biol Lett       Date:  2019-06-06       Impact factor: 5.787

6.  Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy.

Authors:  Mikołaj Piotr Zaborowski; Patrycja Stefens-Stawna; Krystyna Osztynowicz; Tomasz Piorunek; Halina Batura-Gabryel; Agnieszka Dyzmann-Sroka; Wojciech Kozubski; Ewa Nowak-Markwitz; Sławomir Michalak
Journal:  Cancer Immunol Immunother       Date:  2020-11-02       Impact factor: 6.968

7.  Cytochrome C as a potential clinical marker for diagnosis and treatment of glioma.

Authors:  Rashmi Rana; Rohit Singh Huirem; Ravi Kant; Kirti Chauhan; Swati Sharma; M H Yashavarddhan; Satnam Singh Chhabra; Rajesh Acharya; Samir Kumar Kalra; Anshul Gupta; Sunila Jain; Nirmal Kumar Ganguly
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

8.  Cytochrome C inhibits tumor growth and predicts favorable prognosis in clear cell renal cell carcinoma.

Authors:  Zhiguo Liu; Xiancheng Zhao; Liang Zhang; Bing Pei
Journal:  Oncol Lett       Date:  2019-10-14       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.